Articles appearing on AJKD ELECTRONIC PAGES are referred to by issue number, a colon, the letter E, and a number.
Page references to Supplement 1 (January 2005), Supplement 2 (March 2005), and Supplement 3 (April 2005) are preceded, respectively, by S1:, S2:, and S3:.
Access recirculation, improvement of urea clearance in dysfunctional hemodialysis catheters and, 883–890
Acetate-free biofiltration, vs. hemodialysis and hemofiltration for ESRD, 437–447
Acid-base disorders, nephrology core curriculum, 941–946
Acidosis, insulin resistance in chronic kidney disease and, 275–280
Acute coronary syndromes, evaulation in adults and pediatric patients, S3:21–22
Acute renal failure (ARF)
after cardiac surgery for carcinoid heart disease, 826–832
after myeloablative vs. nonmyeloablative bone marrow transplantation, 502–509
antiviral drug-induced, 804–817
core nephrology curriculum, 614–618
dosage of renal replacement therapies and, 1136–1140
endothelin-1 expression in adult-onset minimal change nephropathy and, 818–825
imatinib mesylate therapy for idiopathic hypereosinophilic syndrome and, 762–768
in long-standing type 2 diabetes mellitus, 429–434
pediatric, epidemiology of, 96–101
in pediatric isolated sarcoid granulomatous interstitial nephritis, 411–414
post-coronary artery bypass graft surgery, genetic polymorphisms and, 519–530
randomized controlled trials, 775–779
with rhabdomyolysis, carnitine palmitoyltransferase II deficiency with, 596–602
risk, nonsteroidal anti-inflammatory drugs and, 531–539
Acyclovir-induced nephrotoxicity, pathogenesis and clinical consequences, 804–817
Adefovir-induced nephrotoxicity, pathogenesis and clinical consequences, 804–817
Adequacy of dialysis
effect on dialysis patient mortality, 127–135
pediatric hemodialysis outcomes and, 303–308
rationale for intradialytic exercise training in ESRD, 912–916
Adherence to hemodialysis fluid restrictions
cognitive behavioral therapy for, 1046–1057
psychological interventions for, 15–27
β-Adrenergic receptor agonist, subcutaneous weight-based dosing for hyperkalemia therapy in CKD, 1040–1045
Advanced oxidation protein products, atherosclerotic cardiovascular events in uremic nondiabetic predialysis patients and, 39–47
Aerobic exercise training, intradialytic, rationale for in ESRD, 912–916
African Americans
genetic polymorphisms associated with renal injury after CABG, 519–530
thrombotic thrombocytopenic purpura with imatinib mesylate therapy, 762–768
Age, phosphate levels and carotid intimal-medial thickness in hemodialysis, 859–865
Albumin, serum
hemodialysis access in pediatric patients and, 303–308
lipoprotein(a) levels in chronic kidney disease and, 28–38
metabolic acidosis of chronic kidney disease and, 978–993
single-pass dialysis with modified CVVH for bilirubin removal, 3:E51
survival of hemodialysis patients and, 565–571
Albumin-creatinine urinary ratio, hormone therapy in postmenopausal women and, 1019–1025
Albuminuria
antioxidant status and, 248–255
hormone therapy in postmenopausal women and, 1019–1025
nutrient intake in nondiabetic middle age population and, 256–266
prediction, dipstick data for, 833–841
preterm birth and, 1010–1018
progression in type 2 diabetes, fenofibrate reduction of, 485–493
Aldosterone antagonists, nonrenal effects in cardiovascular disease and, 233–247
Allergic contact dermatitis and eosinophilia, hemodialysis cannula and, 2:E23
Alport syndrome
with anti-GBM autoantibodies and type IV collagen defects, 743–748
necrotizing and crescentic glomerulonephritis in young adult male, 956–960
Ambulatory blood pressure monitoring, in chronic kidney disease, 994–1001
ANCAs. See Antineutrophil cytoplasmic antibodies
Ancestral mutations, ARPKD haplotyping for, 77–87
Anemia
cognitive impairment in dialysis patients and, 448–462
intractable, in hemodialysis patients, 136–147
management
effect on dialysis patient mortality, 127–135
guidelines for dialysis patients, S3:68
vascular access in pediatric hemodialysis patients and, 303–308
nephrology core curriculum, 1121–1122
protection, leptin effect on rHuEPO response in long-term hemodialysis, 1073–1083
Angiotensin-converting enzyme genetic polymorphisms, risk of renal injury after CABG and, 519–530
Angiotensin receptor polymorphisms, with renal injury after CABG, 519–530
Antibiotics, reversible nephrogenic diabetes insipidus and, 626–637
Antifungals, reversible nephrogenic diabetes insipidus and, 626–637
Anti-glomerular basement membrane glomerulonephritis
autoreactive IgA antibody and, 397–406
in differential diagnosis of pulmonary-renal syndromes, 743–748
in long-standing type 2 diabetes mellitus, 429–434
with membranous nephropathy, corticosteroid therapy for, 4:E67
Anti-HCV, prevalence prior to ESRD, 684–689
Antineoplastic agents, causes of reversible nephrogenic diabetes insipidus and, 626–637
Antineutrophil cytoplasmic antibodies (ANCAs)
placental transmission in newborn with pulmonary-renal syndrome, 758–761
rapidly progressive glomerulonephritis and, 950–955
Antioxidants
microalbuminuria and, 248–255
sleep apnea syndrome in ESRD, coronary artery disease and, 875–882
Antivirals
induction of nephrotoxicity, 804–817
reversible nephrogenic diabetes insipidus and, 626–637
Apheresis, effect on proteinuria and podocyte excretion in diabetic nephropathy, 48–53
Apolipoprotein A-1/B, insulin resistance in chronic kidney disease and, 275–280
Apolipoprotein E polymorphisms, with renal injury after CABG, 519–530
Apolipoprotein(a) polymorphisms, management guidelines for dialysis patients, S3:95–102
Apoprotein(a), lipoprotein(a) levels in chronic kidney disease and, 28–38
Arachidonic acid, incident nephrolithiasis and, 267–274
ARF. See Acute renal failure
ARIC (Atherosclerosis Risk in Communities Study), periodontal disease-renal insufficiency association, 650–657
Aristolochic acid-associated nephropathy, transitional cell carcinoma and, 407–410
Arrhythmia, modulation of potassium balance in, 233–247
Arterial calcification, arterial stiffness in renal patients and, 965–977
Arterial stiffness
in hemodialysis patients, renin-angiotensin system and, 866–874
management guidelines for dialysis patients, S3:69–75
in renal patients, 965–977
stepwise increase in chronic kidney disease stages, 494–501
Arteriovenous fistula
thrombosis, hyperhomocysteinemia and, 702–707
vascular access survival, in children on long-term hemodialysis, 708–714
Arteriovenous synthetic grafts, vascular access survival on long-term hemodialysis, 708–714
Ascorbic acid (ascorbate)
long-term IV supplementation, calcium oxalate supersaturation in hemodialysis patients, 540–549
microalbuminuria and, 248–255
Aspirin
for dialysis patients, S3:114
safety/efficacy for chronic kidney disease patients, 473–484, 607–609
Atherosclerosis
arterial stiffness in chronic kidney disease and, 494–501
prediction in uremic nondiabetic predialysis patients, 39–47
Atherosclerosis Risk in Communities Study (ARIC), periodontal disease-renal insufficiency association, 650–657
Atriovenous fistulae, urea clearance, anemia management and serum albumin in pediatric patients, 303–308
Atriovenous grafts, urea clearance, anemia management and serum albumin in pediatric patients, 303–308
Atypical D(-) hemolytic uremic syndrome, from factor H deficiency, plasma therapy for, 415–421
Augmentation index, determination of arterial stiffness in renal patients, 965–977
Australia, rationale for intradialytic exercise training in ESRD, 912–916
Autoantibody assays, in differential diagnosis of pulmonary-renal syndromes, 743–748
Automatic external defibrillators, for cardiac events during dialysis, S3:37–38
Autosomal recessive polycystic kidney disease, improvement of molecular diagnostics by haplotype analysis, 77–87
Bereavement, family perspective on ESRD deaths, 154–161
Bicarbonate
insulin resistance in chronic kidney disease and, 275–280
renal tubular, metabolic acidosis of chronic kidney disease and, 978–993
Bilirubin removal, modified CVVH with single-pass albumin dialysate for, 3:E51
Bioavailabilty, of oral-dose voriconazole in peritoneal dialysis, 162–166
Bioimpedance, of fluid status in peritoneal dialysis, nutritional status and, 891–902
Biomarkers, current knowledge of, S3:81–89
Bisphosphonates, for preventing bone disease in kidney transplant recipients, 638–649
Blood pressure
arterial stiffness in chronic kidney disease and, 494–501
management guidelines for dialysis patients, S3:49–57
in pediatric patients on long-term dialysis, 309–315
relationship of salt intake to progression of CKD and, 176–188
renal artery peak systolic flow velocity in elderly and, 842–850
Blood pump speed, urea clearance in dysfunctional hemodialysis catheters and, 883–890
Body fat content, rHuEPO response in long-term hemodialysis and, 1073–1083
Body weight, management guidelines for dialysis patients, S3:90–91
Bone disease, metabolic acidosis of chronic kidney disease and, 978–993
Bone marrow emboli, in multiple myeloma, 619–623
Bone marrow transplantation, myeloablative vs. nonmyeloablative, ARF after, 502–509
Bone mineral density, increasing in kidney transplant recipients, 638–649
Bone morphogenetic protein antagonist expression, in diabetic nephropathy, 1034–1039
Brain infarction, in maintenance hemodialysis patients, 1058–1066
Calcidiol deficiency, prevalence in chronic kidney disease, 1026–1033
Calcific uremic arteriolopathy calciphylaxis, nephrology core curriculum, 1126–1127
Calcium
abnormalities, management guidelines for dialysis patients, S3:69–75
normal physiology of, 213–215
CAPD (continuous ambulatory peritoneal dialysis), peritonitis development compared with CCPD, 372–380
Carcinoid heart disease, ARF after cardiac surgery for, 826–832
Cardiac hypertrophy, circulating soluble vascular cell adhesion molecule 1 and, 715–729
Cardiac surgery
for carcinoid heart disease, ARF after, 826–832
postoperative renal injury, genetic polymorphisms and, 519–530
Cardiomyopathy, evaulation in adults and pediatric patients, S3:30–33
Cardiopulmonary bypass postoperative renal injury, genetic polymorphisms and, 519–530
Cardiovascular disease
arterial stiffness in chronic kidney disease and, 494–501
with chronic kidney disease, epidemiology of, 223–232, S3:8–9
circulating soluble vascular cell adhesion molecule 1 and, 715–729
evaulation in adults and pediatric patients, S3:17–44
hemodialysis complications, nephrology core curriculum, 1122–1123
metabolic acidosis of chronic kidney disease and, 978–993
morbidity, arterial stiffness in renal patients and, 965–977
mortality, in hemodialysis patients, 119–126, 324–333
outcomes of percutaneous coronary interventions in CKD, 1002–1009
pediatric, epidemiology of, S3:10–15
risk in CKD, safety/efficacy of aspirin and simvastatin for, 473–484
Cardiovascular Health Study, renal duplex sonography parameters associated with renal parenchymal changes in elderly, 842–850
Cardiovascular risk factors
influence of hypertension on mortality in hemodialysis patients and, 112–118
nutrient intake and microalbuminuria in nondiabetic middle age population, 256–266
Carnitine palmitoyltransferase II deficiency, with rhabdomyolysis and ARF, 596–602
Carotenoids, microalbuminuria and, 248–255
Carotid artery intimal-medial thickness, serum phosphate levels in hemodialysis and, 859–865
Case-control study, maternal urine albumin excretion and pregnancy outcome, 1010–1018
cbl C disease, late-onset thrombocytic microangiopathy with factor H mutation, 588–595
CCPD (continuous cycling peritoneal dialysis), peritonitis development compared with CAPD, 372–380
C4d, peritubular capillary deposition in transplant glomerulitis, 1084–1089
CD68, prognosis for renal dysfunction in children with MPGN-1 and, 510–518
Central diabetes insipidus, with lymphocytic hypophysitis unveiled by glucocorticoid replacement, 197–200
Central venous catheters
urea clearance, anemia management and serum albumin in pediatric patients, 303–308
vascular access survival in long-term hemodialysis of children, 708–714
Cerebrovascular disease
cognitive impairment in dialysis patients and, 448–462
evaulation in adults and pediatric patients, S3:39–42
risk factors, cognitive impairment in dialysis patients and, 448–462
Chemotherapy, acute renal failure after myeloablative HCT, 502–509
Children
acute renal failure epidemiology in, 96–101
cardivascular disease epidemiology in, S3:10–15
chromophobe renal cell carcinoma in living-related kidney transplant recipient, 6:E105
hypertension in long-term dialysis, 309–315
isolated sarcoid granulomatous interstitial nephritis in, 411–414
late-onset thrombocytic microangiopathy with factor H mutation, 588–595
on long-term hemodialysis, vascular access survival and, 708–714
with MPGN-1, prognostic markers for, 510–518
pulmonary-renal syndrome with placental transmission of ANCAs, 758–761
vascular access, urea clearance, anemia management and serum albumin in hemodialysis, 303–308
Cholesterol-lowering therapy, effect on mortality of hemodialysis patients, 119–126
Chronic kidney disease (CKD)
anti-HCV prevalence in, 684–689
arterial stiffness in, 965–977
calcidiol deficiency prevalence in, 1026–1033
and cardiovascular disease, epidemiology of, 223–232
in Chinese patients, application of GFR-estimating equations in, 463–472
clinical pharmacists in management of, 1105–1118
cognitive impairment in menopausal women and, 66–76
dipstick data for predicting proteinuria, 833–841
heart disease with hypertension and diabetes in, 316–323
home blood pressure monitoring in, 994–1001
insulin resistance in, 275–280
lipoprotein(a) levels in, 28–38
measure of satisfaction with treatment for, 572–579
metabolic acidosis, 978–993
outcomes of percutaneous coronary interventions in, 1002–1009
periodontal disease and, 650–657
and proteinuria in Fabry disease, 5:E82
quality of life in, 658–666
restless legs syndrome in kidney transplant recipients, 388–396
safety/efficacy of simvastatin and aspirin for, 473–484, 607–609
salt intake and progression of, 176–188
screening strategies and programs, 201–208
severity, arterial stiffness and, 494–501
subcutaneous terbutaline therapy for hyperkalemia in, 1040–1045
thoracic hemorrhage from ectopic mediastinal parathyroid gland, 6:E109
Cidofovir-induced nephrotoxicity, pathogenesis and clinical consequences, 804–817
CIHD (conventional intermittent hemodialysis), vs. daily hemodialysis, 798–803
Cilium, proximal tubular motile, in renal sarcoidosis with hypercalcemia, 1096–1099
Cobalamin processing deficiency, late-onset thrombocytic microangiopathy with factor H mutation, 588–595
Cochrane Renal Group Report, 775–779
Cockcroft-Gault equation, application in Chinese patients with CKD, 463–472
Cognition
in dialysis patients, 448–462
in menopausal women with chronic kidney disease, 66–76
Cognitive behavioral intervention, to enhance adherence to hemodialysis fluid restrictions, 1046–1057
Common variable immunodeficiency, with renal granuloma and hypocalcemia, 5:E90
Comorbidity, intractable anemia in hemodialysis patients, 136–147
Complement activation via lectin pathway
in Henoch-Schönlein purpura nephritis, 295–302
in renal sarcoidosis, 580–587
Complement factor H deficiency, hemolytic uremic syndrome from, plasma therapy for, 415–421
Complement regulators, late-onset thrombocytic microangiopathy with factor H mutation, 588–595
Compliance with hemodialysis fluid restrictions
sndx2}cognitive behavioral therapy for, 1046–1057
psychological interventions for, 15–27
Congestive heart failure, modulation of potassium balance in, 233–247
Conjunctival calcification, with vascular calcification in dialysis patients, 550–556
Continuous ambulatory peritoneal dialysis (CAPD), peritonitis development compared with CCPD, 372–380
Continuous cycling peritoneal dialysis (CCPD), peritonitis development compared with CAPD, 372–380
Continuous venovenous hemodialfiltration, modification with single-pass albumin dialysate, 3:E51
Continuous venovenous hemofiltration (CVVH), lorazepam and midazolam pharmacokinetics in, 360–371
Contrast nephropathy, randomized controlled trials, 775–779
Conventional intermittent hemodialysis (CIHD), vs. daily hemodialysis, 798–803
Corneal calcification, association with vascular calcification in dialysis patients, 550–556
Coronary artery calcification, sleep apnea syndrome in ESRD, antioxidant status and, 875–882
Coronary artery disease
chronic, evaulation in adults and pediatric patients, S3:23–26
evaulation in adults and pediatric patients, S3:18–20
sleep apnea syndrome in ESRD, antioxidant status and, 875–882
Corticosteroids, for anti-glomerular basement membrane glomerulonephritis with membranous nephropathy, 4:E67
Costs, of delivering medications in dialysis field, 917–925
C-reactive protein
atherosclerosis in uremic nondiabetic predialysis patients and, 39–47
lipoprotein(a) levels in chronic kidney disease and, 28–38
Creatinine, serum
association of genetic polymorphisms with renal injury risk after CABG, 519–530
insulin resistance in chronic kidney disease and, 275–280
pitfalls of estimating GFR from, 610–613
statins and, 2–14
Creatinine clearance
insulin resistance in chronic kidney disease and, 275–280
statins and, 2–14
Creatinine-protein urinary ratio, in predicting proteinuria, 833–841
Crescentic glomerulonephritis
autoreactive IgA antibody and, 397–406
in long-standing type 2 diabetes mellitus, 429–434
systemic lupus erythematosus and, 950–955
Crescents, with IgA nephropathy in kidney transplant recipients, 167–175
Crohn disease, hypercalcemia from 1,25-dihydroxyvitamin D excess in, 1:E3
Cross-sectional cohort study, of calcidiol deficiency prevalence in CKD, 1026–1033
Cryoglobulinemia, type III, in renal cortical necrosis, 5:E79
Crystal nephropathy, antiviral-induced, 804–817
CVVH (continuous venovenous hemofiltration), lorazepam and midazolam pharmacokinetics in, 360–371
Cystic fibrosis, unusual presentation in adult, 3:E41
Cytokine production, mononuclear cell senescence in long-term hemodialysis and, 353–359
Cytomegalovirus-induced recurrence, of factor H mutation associated hemolytic uremic syndrome after transplant, 1:E12
Daily hemodialysis
gabapentin-induced myopathy and, 6:E100
rationale for, 793–797, 798–803
DAIS (Diabetes Atherosclerosis Intervention Study), fenofibrate reduction of microalbuminuria in type 2 diabetes, 485–493
Delivery costs, for dialysis patient medications, 917–925
Diabetes Atherosclerosis Intervention Study (DAIS), fenofibrate reduction of microalbuminuria in type 2 diabetes, 485–493
Diabetes mellitus
with chronic kidney disease, pharmacists in management of, 1105–1118
fenofibrate reduction of microalbuminuria progression in, 485–493
with hypertension and heart disease in ESRD, 316–323
management guidelines for dialysis patients, S3:46–48
nonfasting non-HDL cholesterol for dyslipidemia management, 1067–1072
outcomes of percutaneous coronary interventions in CKD, 1002–1009
phosphate levels and carotid intimal-medial thickness in hemodialysis patients, 859–865
preventive foot care for dialysis patients, S3:113
stroke in maintenance hemodialysis patients and, 1058–1066
Diabetic nephropathy
case reports, 429–434
with ESRD, renoprotection in, 281–287
extracellular signal-regulated kinase and p38 in, 54–65
glomerular VEGF gene expression and structural glomerular changes in, 288–294
gremlin expression in, 1034–1039
LDL apheresis effect on proteinuria and podocyte excretion, 48–53
randomized controlled trials, 775–779
Dialysis. See Hemodialysis; Peritoneal dialysis
Dialysis membranes, high-flux, survival in hemodialysis patients and, 565–571
Dialyzer clearance, hemodialysis prescription and, 798–803
Dietary risk factors, for nephrolithiasis, 267–274
1,25-Dihydroxyvitamin D excess, hypercalcemia in Crohn disease and, 1:E3
Dipstick hematuria, in pregnancy, 667–673
Dipstick protein, in predicting pathological proteinuria, 833–841
Dose of dialysis
patient mortality and, 127–135
renal replacement therapies for acute renal failure, 1136–1140
Drug therapy. See also specific drugs
cognitive impairment in dialysis patients and, 448–462
costs, for dialysis patients, 917–925
reversible nephrogenic diabetes insipidus and, 626–637
Dyslipidemia
evaulation in adults and pediatric patients, S3:34–36
management guidelines for dialysis patients, S3:58–59
non-fasting non-HDL cholesterol levels for management in hemodialysis, 1067–1072
Elderly, renal fibromuscular dysplasia in, 4:E63
Electron microscopy, of CPT II deficiency with rhabdomyolysis and ARF, 596–602
End-diastolic velocity, systolic blood pressure in elderly and, 842–850
End-of-life care, for dialysis patients, improving, 209–212
Endothelial cell injury, steroid-responsive idiopathic glomerular capillary endotheliosis, 1090–1095
Endothelial nitric oxide synthase, polymorphisms associated with renal injury after CABG, 519–530
Endothelial vascular dysfunction, pregnancy outcome and, 1010–1018
Endothelin-1, expression in adult-onset minimal change nephropathy with/without ARF, 818–825
End-stage renal disease (ESRD)
arterial stiffness improvement in hemodialysis patients, 866–874
arterial stiffness in, 965–977
deaths, family perspectives on, 154–161
with diabetic nephropathy, renoprotection in, 281–287
fibrate-induced rhabdomyolysis in, plasma exchange for, 3:E57
heart disease with diabetes and hypertension in, 316–323
impact of statins on kidney function in, 2–14
improving care for, 209–212
minimal use of hemofiltration in U.S., 603–606
patient autonomy, increased transplantation and survival of dialysis patients, 730–742
in pediatric patients, hypertension with long-term dialysis, 309–315
physical activity effect on mortality rates in, 690–01
prevalence of anti-HCV and, 684–689
rationale for intradialytic exercise training in, 912–916
restless legs syndrome in kidney transplant recipients, 388–396
sildenafil for erectile dysfunction in male peritoneal dialysis patients, 381–387
with sleep apnea, coronary artery disease and antioxidant status in, 875–882
stroke in maintenance hemodialysis patients, 1058–1066
systematic review of hemodialysis, hemofiltration and AFB for, 437–447
URR and hematocrit effets on mortality outcomes, 127–135
Energy intake, rHuEPO response in long-term hemodialysis and, 1073–1083
Eosinophilia and allergic contact dermatitis, with hemodialysis cannula, 2:E23
Epidemiology
of chronic kidney disease and cardiovascular disease, 223–232
of pediatric acute renal failure, 96–101
Erectile dysfunction, sidenafil for in male peritoneal dialysis patients, 381–387
Erythropoiesis, body mass index in long-term hemodialysis and, 1073–1083
Erythropoietin, recombinant human
intractable anemia in hemodialysis, disease burden and, 136–147
pure red cell aplasia induced by, rapid resolution of, 6:E97
response in long-term hemodialysis, hyperlipidemia and, 1073–1083
vascular access in pediatric hemodialysis patients and, 303–308
Estrogen, urinary albumin excretion in postmenopausal women and, 1019–1025
Exercise
guidelines for dialysis patients, S3:60–67
mortality rates in ESRD patients and, 690–701
tailored regimens for kidney transplant recipients, 769–774
Extracellular signal-regulated kinase, in diabetic nephropathy, 54–65
Fabry disease, proteinuria and chronic renal failure in, 5: E82
Factor H mutation
late-onset thrombocytic microangiopathy with, 588–595
posttransplantation cytomegalovirus-induced recurrence of HUS, 1:E12
Falls, accidental, incidence in hemodialysis patients, 148–153
Family history, guidelines for dialysis patients, S3:106–110
Family perspectives, on deaths of dialysis patients, 154–161
Fanconi syndrome, induced by monoclonal Vκ 3 light chain in Waldenström macroglobulinemia, 749–757
Fasting, non-HDL cholesterol for dyslipidemia management in hemodialysis, 1067–1072
Fenofibrate, reduction of microalbuminuria progression in type 2 diabetes, 485–493
Fever, tularemia in kidney transplant patient, 926–929
Fibrate-induced rhabdomyolysis, in ESRD, plasma exchange for, 3:E57
Fibrinogen
atherosclerosis in uremic nondiabetic predialysis patients and, 39–47
insulin resistance in chronic kidney disease and, 275–280
Fibromuscular dysplasia, in elderly, 4:E63
Fish oil, incident nephrolithiasis and, 267–274
Fluid overload, in the development of malnutrition in peritoneal dialysis patients, 891–902
Fluid restriction adherence for hemodialysis patients
cognitive behavioral therapy for, 1046–1057
psychological interventions for, 15–27
Foot care, preventive, for diabetic dialysis patients, S3:113
Fraction excretion, of uric acid in severe acute respiratory syndrome, 88–95
Fractures
from falls in hemodialysis patients, 148–153
preventing, in kidney transplant recipients, 638–649
Frame shift, of CPT II gene, with rhabdomyolysis and ARF, 596–602
Francisella tularensis , in blood of kidney transplant patient, 926–29
Fresh frozen plasma, for atypical hemolytic uremic syndrome caused by factor H deficiency, 415–421
Fungal peritonitis, voriconazole pharmacokinetics in peritoneal dialysis, 162–166
Gabapentin-induced myopathy, short daily hemodialysis for, 6:E100
Ganciclovir, and plasma exchange for posttransplantation cytomegalovirus-induced recurrence of atypical HUS, 1:E12
Genetic polymorphisms
apo(a), management guidelines for dialysis patients, S3:95–102
with renal injury after CABG, 519–530
Genetics, management guidelines for dialysis patients and, S3:106–110
Geographic location, calcidiol deficiency prevalence in chronic kidney disease and, 1026–1033
Gestational hypertension, microscopic hematuria and, 667–673
GFR. See Glomerular filtration rate
Glomerular capillary endotheliosis, steroid-responsive idiopathic, 1090–1095
Glomerular disease recurrence, posttransplantation nephrotic syndrome and, 1129–1135
Glomerular filtration rate (GFR)
arterial stiffness in chronic kidney disease and, 494–501
in Chinese patients with CKD, estimates of, 463–472
estimating from creatinine concentrations, pitfalls of, 610–613
lipoprotein(a) levels in chronic kidney disease and, 28–38
metabolic acidosis of chronic kidney disease, 978–993
periodontal disease and, 650–657
restless legs syndrome in kidney transplant recipients, 388–396
statins and, 2–14
Glomerular filtration rate-estimating equations, pitfalls of, 610–613
Glomerulonephritis
in idiopathic glomerular capillary endotheliosis, 1090–1095
in long-standing type 2 diabetes mellitus, 429–434
microscopic hematuria in pregnancy and, 667–673
Glomerulopathy, antiviral-induced, 804–817
Glucocorticoid-deficiency associated hyponatremia, with masked diabetes insipidus and lymphocytic hypophysitis, 197–200
Glucose homeostasis, metabolic acidosis of chronic kidney disease and, 978–993
Goodpasture syndrome
false positive diagnosis with type IV collagen defects, 743–748
recurrent, secondary to autoreactive IgA antibody, 397–406
Graft vs. host disease, nephrotic syndrome in peripheral blood stem cell transplant recipients, 780–785
Granulomatous interstitial nephritis, isolated sarcoid, in child, 411–414
Gremlin, expression in diabetic nephropathy, 1034–1039
Growth hormone, metabolic acidosis of chronic kidney disease and, 978–993
Haplotype analysis, of autosomal recessive polycystic kidney disease, 77–87
HCV RNA assay, incidence/patterns of HCV seroconversion in hemodialysis patients, 334–343
Health surveys, relationship of microalbuminuria and antioxidant status, 248–255
Heart disease, with hypertension and diabetes in ESRD, 316–323
Heart failure, risk of ARF in nonsteroidal anti-inflammatory drug users, 531–539
Heart surgery, postoperative renal injury, genetic polymorphisms and, 519–530
Hematopoietic cell transplantation, myeloablative vs. nonmyeloablative, acute renal failure after, 502–509
Hematuria, microscopic, in pregnancy, 667–673
Hemodiafiltration, vs. AFB and hemodialysis for ESRD, 437–447
Hemodialysis
access. See Vascular access
alternative regimens, 793–797, 798–803
arterial stiffness improvement by renin-angiotensin system blockade, 866–874
association of corneal calcification with vascular calcification in, 550–556
calcium oxalate supersaturation from intravenous vitamin C, 540–549
carotid intimal-medial thickness, serum phosphate and, 859–865
cognitive function in, 448–462
complications, nephrology core curriculum, 1119–1128
daily, rationale for, 793–797
discordance of mortality and cardiovascular risk in, 112–118
effect on arterial wall properties, 965–977
ESRD, effect of physical activity on mortality rates, 690–701
fluid-intake restrictions, psychological interventions for adherence improvement, 15–27
improving end-of-life care for, 209–212
incidence, risk and complications from falls, 148–153
incidence/patterns of HCV seroconversion in, 334–343
interleukin-6 prediction of cardiovascular mortality in, 324–333
intractable anemia in, 136–147
leg pain from bilateral focal recurrent myositis, 1:E7
long-term. See Long-term hemodialysis
long-term intravenous supplementation, calcium oxalate supersaturation and, 540–549
metabolic acidosis of chronic kidney disease and, 978–993
mortality reduction, statin therapy and, 119–126
non-fasting non-HDL for dyslipidemia management in, 1067–1072
patient autonomy association with increased transplantation and survival, 730–742
for phenytoin intoxication, 189–192
randomized controlled trials, 775–779
rationale for intradialytic exercise training in ESRD, 912–916
restless legs syndrome in kidney transplant recipients and, 388–396
sleep apnea syndrome in ESRD, coronary artery disease, antioxidant status and, 875–882
survival, dialyzer membrane permeability and, 565–571
survival, effect of URR and hematocrit on, 127–135
vascular access thrombosis, hyperhomocysteinemia and, 702–707
vs. AFB and hemofiltration for ESRD, 437–447
Hemodialysis cannula, allergic contact dermatitis and eosinophilia associated with, 2:E23
Hemodialysis catheters, dysfunctional, improvement of urea clearance by reversing line position, 883–890
Hemodialysis grafts, anastomotic venous stenosis, percutaneous balloon cryoplasty for, 2:E27
Hemodynamics, perioperative compromise, ARF after cardiac surgery for carcinoid heart disease and, 826–832
Hemofiltration
minimal usage in U.S., 603–606
for phenytoin intoxication, 189–192
vs. hemodialysis and AFB for ESRD, 437–447
Hemoglobin
restless legs syndrome in kidney transplant recipients, 388–396
vascular access in pediatric hemodialysis patients and, 303–308
Hemolytic uremic syndrome (HUS)
atypical from factor H deficiency, plasma therapy for, 415–421
with factor H mutation, posttransplantation cytomegalovirus-induced recurrence of, 1:E12
late-onset thrombocytic microangiopathy with factor H mutation, 588–595
in pediatric acute renal failure, 96–101
Henoch-Schönlein purpura nephritis, activation of lectin complement pathway in, 295–302
Hepatitis, renal function impairment and hepatitis E virus in kidney transplant recipient, 193–196
Hepatitis C virus
prevalence prior to ESRD, 684–689
seroconversion, incidence/patterns in hemodialysis patients, 334–343
Hepatitis E virus, in kidney transplant recipient, acute hepatitis and renal function impairment in, 193–196
Herba Aristolochia Mollissemae , nephropathy in, 407–410
Hereditary nephritis, of Alport type, in young adult male, 956–960
High-flux hemodialysis
for phenytoin intoxication, 189–192
safety/efficacy of long-term use of citrate anticoagulation, 557–564
High-resolution ultrasonography, with 123 I/ 99m Tc sestamibi scintigraphy for localization of hyperplastic parathyroid glands, 344–352
Hodgkin disease, with IgA nephropathy, 1:E16
Home blood pressure monitoring, in chronic kidney disease, 994–1001
Homocysteine
cognitive impairment in dialysis patients and, 448–462
management guidelines for dialysis patients, S3:95–98
vascular access thrombosis and, 702–707
Hormone therapy, urinary albumin excretion in postmenopausal women and, 1019–1025
HUS. See Hemolytic uremic syndrome
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. See Statins
Hydroxyvitamin D, prevalence in chronic kidney disease, 1026–1033
Hypercalcemia
diagnosis and treatment of, 215–216
excess 1,25-dihydroxyvitamin D in Crohn’s disease and, 1:E3
with sarcoidosis, proximal tubular motile cilia in, 1096–1099
Hypereosinophilic syndrome, imatinib mesylate therapy causing thrombotic thrombocytopenic purpura, 762–768
Hyperhomocysteinemia, vascular access thrombosis and, 702–707
Hyperinsulinemia-induced renal magnesium, in metabolic syndrome, 851–858
Hyperkalemia
nephrology core curriculum, 948–949
subcutaneous terbutaline therapy in CKD, 1040–1045
Hyperlipidemia
with chronic kidney disease, pharmacists in management of, 1105–1118
statin therapy, effect on mortality of hemodialysis patients, 119–126
Hypermagnesemia, diagnosis and treatment of, 217–218
Hyperphosphatemia, diagnosis and treatment of, 217
Hyperplastic parathyroid glands, localization by combining ultrasonography and 123 I/ 99m Tc sestamibi scintigraphy, 344–352
Hypertension
angiotensin receptor-blocking agent as renoprotective agent in ESRD with diabetic nephropathy, 281–287
with chronic kidney disease, pharmacists in management of, 1105–1118
with heart disease and diabetes in ESRD, 316–323
home blood pressure monitoring in CKD, 994–1001
in isolated sarcoid granulomatous interstitial nephritis in child, 411–414
modulation of potassium balance in, 233–247
mortality risk in hemodialysis patients and, 112–118
in pediatric patients on long-term dialysis, 309–315
relationship of salt intake to progression of CKD and, 176–188
risk of ARF in nonsteroidal anti-inflammatory drug users, 531–539
stroke in maintenance hemodialysis patients and, 1058–1066
Hypoalbuminemia
metabolic acidosis of chronic kidney disease and, 978–993
with phenytoin intoxication, high-flux dialysis for, 189–192
Hypocalcemia
with common variable immunodeficiency and renal granuloma, 5:E90
diagnosis and treatment of, 216
Hypokalemia
cardiovascular implications of, 233–247
nephrology core curriculum, 947–948
Hypomagnesemia, diagnosis and treatment of, 218
Hyponatremia, glucocorticoid-deficiency associated with lymphocytic hypophysitis and masked diabetes insipidus, 197–200
Hypophosphatemia
diagnosis and treatment of, 216–217
in metabolic syndrome, 851–858
Hyposthenuria, reversible nephrogenic diabetes insipidus and, 626–637
Hypouricemia, in severe acute respiratory syndrome, 88–95
Idiopathic hypotension, management guidelines for dialysis patients, S3:76–80
IgA-κ antibodies, recurrent Goodpasture disease and, 397–406
Imatinib mesylate, thrombotic thrombocytopenic purpura associated with, 762–768
Immunity, hemodialysis complications, nephrology core curriculum, 1124–1125
Immunoadsoroption, for rapid resolution of erythropoietin-induced pure red cell aplasia, 6:E97
Immunofluorescence, vs. immunoperoxidase for renal biopsy assessment, 674–683
Immunoglobulin A
autoantibodies, recurrent Goodpasture disease and, 397–406
mesangial deposits in Henoch-Schönlein purpura nephritis, 295–302
nephropathy
with crescents in kidney transplant recipients, 167–175
with Hodgkin disease, 1:E16
Immunoglobulin G subclass distribution, in biopsy specimen with membranous
nephropathy and AGBM glomerulonephritis, corticosteroid therapy for, 4:E67
Immunohistochemistry, immunoperoxidase vs. immunofluorescence for renal biopsy assessment, 674–683
Immunoperoxidase, vs. immunofluorescence for renal biopsy assessment, 674–683
Immunosuppression
nephrotic syndrome in peripheral blood stem cell transplant recipients, 780–785
tularemia in kidney transplant patient, 926–929
Indinavir-induced nephrotoxicity, pathogenesis and clinical consequences, 804–817
Individual differences, in treatment satisfaction in chronic kidney failure, 572–579
Infection, hemodialysis complications, nephrology core curriculum, 1124–1125
Inflammation
atherosclerosis in uremic nondiabetic predialysis patients and, 39–47
current knowledge of, S3:82–86
in hemodialysis, mononuclear cell senescence and, 353–359
in kidney, impact of statins on, 2–14
metabolic acidosis of chronic kidney disease and, 978–993
periodontal disease association with renal insufficiency, 650–657
Infliximab, for isolated sarcoid granulomatous interstitial nephritis in child, 411–414
In situ hybridization, glomerular VEGF gene expression in diabetic nephropathy, 288–294
Insulin
metabolic acidosis of chronic kidney disease and, 978–993
renal magnesium in metabolic syndrome and, 851–858
resistance, in chronic kidney disease, 275–280
Intensive care patients on CVVH, lorazepam and midazolam pharmacokinetics in, 360–371
Interdialytic weight gain
}cognitive behavioral therapy to improve hemodialysis fluid restrictions, 1046–1057
psychological interventions to improve fluid-intake restrictions in hemodialysis patients and, 15–27
Interleukin-6, prediction of cardiovascular mortality in hemodialysis, 324–333
Interleukin-8, renal hyperuricemia in severe acute respiratory syndrome and, 88–95
Intermediate-density lipoprotein cholesterol, suppression with improved arterial stiffness in hemodialysis patients, 866–874
Intimal-medial thickness, in hemodialysis patients, serum phosphate levels and, 859–865
Intracerebral hemorrhage, in maintenance hemodialysis patients, 1058–1066
Intradialytic complications, nephrology core curriculum, 1127–1128
Irbesartan, renoprotection in ESRD with diabetic nephropathy, 281–287
Irbesartan Diabetic Nephropathy Trial, proteinuria reduction and progression in ESRD in diabetic nephropathy, 281–287
Iron deficiency, restless legs syndrome in kidney transplant recipients, 388–396
Kidney allograft, IgA nephropathy with crescents in, 167–175
Kidney concentration ability, reversible nephrogenic diabetes insipidus and, 626–637
Kidney Disease Outcomes Quality Initiative (K/DOQI), improvements in dialysis patient mortality and, 127–135
Kidney Disease Quality of Life (KDQOL), assessment of quality of life in CKD, 658–666
Kidney stones, fatty acid intake and, 267–274
Kidney transplant recipients
acute hepatitis and HEV in, 193–196
acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in, 2:E33
anti-glomerular basement membrane disease with autoreactive IgA antibodies, 397–406
IgA nephropathy with crescents in, 167–175
interventions to prevent bone disease in, 638–649
pediatric living-related, chromophobe renal cell carcinoma in, 6:E105
restless legs syndrome in, 388–396
scleroderma renal crisis despite angiotensin II blockade, 930–934
with systemic lupus erythematosus, long-term prognosis for, 903–911
tailored exercise regimens for, 769–774
tularemia in, 926–929
Lectin complement pathway activation
in Henoch-Schönlein purpura nephritis, 295–302
in renal sarcoidosis and, 580–587
Leg pain, in hemodialysis patient from bilateral focal recurrent myositis, 1:E7
Leptin, rHuEPO response in long-term hemodialysis, 1073–1083
Lifestyles, nutrient intake and microalbuminuria in middle age middle age nondiabetic population, 256–266
Light chain cast nephropathy, in multiple myeloma, 619–623
Linoleic acid, incident nephrolithiasis and, 267–274
Lipid-independent effects, of statins in kidney, 2–14
Lipid levels, serum
lipoprotein(a) levels in chronic kidney disease and, 28–38
non-fasting, for dyslipidemia management in hemodialysis, 1067–1072
Lipoprotein(a)
in chronic kidney disease, 28–38
management guidelines for dialysis patients, S3:95–102
Lithium, reversible nephrogenic diabetes insipidus and, 626–637
Long intermittent hemodialysis, vs. daily hemodialysis, 798–803
Long-term hemodialysis
hypertension in pediatric patients and, 309–315
leptin effect on rHuEPO response in, 1073–1083
mononuclear cell senescence and, 353–359
safety/efficacy of citrate anticoagulation in, 557–564
vascular access survival in children and young adults, 708–714
Lorazepam, pharmacokinetics in CVVH patients, 360–371
Losartan, improvement of arterial stiffness in hemodialysis patients, 866–874
Low-density lipoprotein apheresis, proteinuria and podocyte excretion in diabetic nephropathy, 48–53
Lupus nephritis, long-term prognosis for renal transplantation and, 903–911
Lymphocytic hypopysitis, with masked diabetes insipidus unveiled by glucocorticoid replacement, 197–200
Magnesium, serum
in metabolic syndrome, 851–858
normal physiology of, 213–215
Maintenance hemodialysis
long-term, safety/efficacy of citrate anticoagulation for, 557–564
stroke incidence in, 1058–1066
Malnutrition
hemodialysis complications, nephrology core curriculum, 1123–1124
management guidelines for dialysis patients, S3:102–106
rHuEPO response in long-term hemodialysis and, 1073–1083
Mannose-binding lectin
in host defense mechanisms, renal sarcoidosis and, 580–587
mesangial deposits in Henoch-Schönlein purpura nephritis, 295–302
Mannose-binding lectin-associated serine protease-1, in Henoch-Schönlein purpura nephritis, 295–302
Mast cell chymase, in ischemic kidney of severe unilateral renovascular hypertension, 3:E45
MDRD equation. See Modification of Diet in Renal Disease equation
Mediastinal tumor, causing thoracic hemorrhage in chronic renal failure, 6:E109
Medical Outcomes Study Short Form-36, assessment of quality of life in CKD, 658–666
Medications. See Drug therapy; specific medications
Melphalan conditioning, for primary amyloidosis, acute renal insufficiency after, 102–111
Membranoproliferative glomerulonephritis type I, prognostic markers in macrophages, 510–518
Membranous nephropathy
and anti-glomerular basement membrane glomerulonephritis, corticosteroid therapy for, 4:E67
nephrotic syndrome in peripheral blood stem cell transplant recipients, 780–785
Menopausal women
with chronic kidney disease, cognitive function in, 66–76
management guidelines for dialysis, S3:110–113
Mesangial matrix, structural changes in diabetic nephropathy, 288–294
Metabolic acidosis
of chronic kidney disease, 978–993
nephrology core curriculum, 941–942
Metabolic alkalosis, nephrology core curriculum, 944–945
Metabolic factors, management guidelines for dialysis patients, S3:90–106
Metabolic syndrome, hypophosphatemia in, 851–858
Methylenetetrahydrofolate reductase (MTHFR) genotype, association of hyperhomocystenemia and vascular access thrombosis, 702–707
Methylprednisolone therapy, for idiopathic glomerular capillary endotheliosis, 1090–1095
Microalbuminuria. See Albuminuria
Microangiopathic hemolytic anemia, associated with imatinib mesylate, 762–768
β 2 Microglobulin, metabolic acidosis of chronic kidney disease and, 978–993
Microscopic polyangiitis, in newborn with placental transmission of ANCAs, 758–761
Midazolam pharmacokinetics, in CVVH patients, 360–371
Minimal change nephropathy
endothelin-1 expression with/without ARF, 818–825
nephrotic syndrome in peripheral blood stem cell transplant recipients, 780–785
Mitogen-activated protein kinase, in diabetic nephropathy, 54–65
Modification of Diet in Renal Disease equation
for Chinese chronic kidney disease patients, 463–472
pitfalls of, 610–613
Molecular adsorbents recirculating system dialysis, for phenytoin intoxication, 189–192
Molecular diagnostics, for ARPKD, improving by haplotype analysis, 77–87
Monoclonal immunoglobulin deposition disease, in multiple myeloma, 619–623
Monoclonal κ light chain, induction of Fanconi syndrome in Waldenström macroglobulinemia, 749–757
Monoclonal proteins, renal insufficiency in multiple myeloma and, 619–623
Monocyte chemoattractant protein-1, in diabetic nephropathy, 54–65
Monocytes, in transplant glomerulitis, peritubular capillary C4d deposition and, 1084–1089
Mononuclear cell senescence, chronic inflammation in long-term hemodialysis and, 353–359
Mortality
after myeloablative vs. nonmyeloablative hematopoietic cell transplantation, 502–509
arterial stiffness in renal patients and, 965–977
cardiovascular in hemodialysis, interleukin-6 prediction of, 324–333
circulating soluble vascular cell adhesion molecule 1 and, 715–729
ESRD, physical activity and, 690–701
of hemodialysis patients, statins and, 119–126
low blood pressure in hemodialysis patients and, 112–118
}patient autonomy and, 730–742
}reduction, URR and hematocrit improvements and, 127–135
MTHFR genotype, hyperhomocystenemia- vascular access thrombosis association and, 702–707
}Multidisciplinary health care providers, in chronic kidney disease management, 1105–1118
Multiple myeloma, complications from, 619–623
Muscle wasting, metabolic acidosis of chronic kidney disease and, 978–993
Mutation, novel familial, in Wilms tumor with slow progressive nephropathy, 1100–N1104
Mycobacterium simiae , as peritoneal dialysis peritonitis pathogen, 5:E75
Myeloid-related protein 8, in macrophages, MPGN-1 progression and, 510–518
Myeloid-related protein 14, in macrophages, MPGN-1 progression and, 510–518
Myeloperoxidase-antineutrophil cytoplasmic antibodies, placental transmission in newborn with pulmonary-renal syndrome, 758–761
Myocardial infarction, modulation of potassium balance in, 233–247
Myopathy, gabapentin-induced, short daily hemodialysis for, 6:E100
Myositis, bilateral focal recurrent, leg pain in hemodialysis patient and, 1:E7
National Health and Nutrition Examination Survey (NHANES), microalbuminuria and antioxidant status in U.S. adults, 248–255
National Kidney Foundation DOQI, clinical practice guidelines for cardiovascular disease in dialysis, S3:1–153
Necrotizing and crescentic glomerulonephritis, in young adult male, Alport syndrome and, 956–960
Neovascularization, glomerular VEGF gene expression in diabetic nephropathy and, 288–294
Nephrogenic diabetes insipidus
antiviral-induced, 804–817
reversible, causes of, 626–637
Nephrolithiasis
core curriculum, 422–428
fatty acid intake and, 267–274
Nephrology, randomized controlled trials, 775–779
Nephrology core curriculum
acid-base disorders, 941–946
acute renal failure, 614–618
calcium, phosphorus and magnesium disorders, 213–218
hemodialysis complications, 1119–1128
nephrolithiasis, 422–428
potassium disorders, 946–949
Nephropathy, slow progressive in Wilms tumor with novel familial WT1 read-through mutation, 1100–1104
Nephrotic syndrome
of diabetic nephropathy, effect of LDL aphresis on proteinuria and podocyte excretion, 48–53
in peripheral blood stem cell transplant recipients, 780–785
posttransplantation, caused by recurrence of glomerular disease, 1129–1135
Nephrotoxicity, antiviral-induced, 804–817
Nested-case-control study, risk of ARF in nonsteroidal anti-inflammatory drug users, 531–539
}Neuropsychological tests, cognitive function in dialysis patients, 448–462
N-3 fatty acids, incident nephrolithiasis and, 267–274
Nocturnal hemodialysis, vs. daily hemodialysis, 793–797, 798–803
Nonfasting, non-HDL cholesterol for dyslipidemia management in hemodialysis, 1067–1072
Non-high-density lipoprotein cholesterol, non-fasting, for dyslipidemia management in hemodialysis, 1067–1072
Non-lipid-dependent effects, of statins in kidney, 2–14
Nonsteroidal anti-inflammatory drugs, acute renal failure risk and, 531–539
Nosocomial transmission, of HCV in hemodialysis patients, 334–343
Nuclear factor kB (NF-kB), in diabetic nephropathy, 54–65
Nutrition
daily hemodialysis and, 798–803
management guidelines for dialysis patients, S3:90–106
microalbuminuria in nondiabetic middle age population and, 256–266
protein concentrations in predicting outcome of hemodialysis patients, 565–571
volume status in peritoneal dialysis patients and, 891–902
Omega-3 fatty acids, management guidelines for dialysis patients, S3:91–94
Osteodystrophy, prevention in kidney transplant recipients, 638–649
Oxalate, supersaturation from long-term intravenous vitamin supplementation, 540–549
Oxidative stress
atherosclerosis in uremic nondiabetic predialysis patients and, 39–47
current knowledge of, S3:86–89
p38, in diabetic nephropathy, 54–65
Pain management, family perspectives on ESRD deaths, 154–161
Paraproteinemia, recurrent Goodpasture’s disease with autoreactive IgA antibodies, 397–406
Parathyroidectomy, localization method for hyperplastic parathyroid glands, 344–352
Parathyroid gland, ectopic mediastinal, secondary hyperparathyroidism with CRF, 6:E109
Parathyroid hormone
abnormalities, management guidelines for dialysis patients, S3:69–75
cognitive impairment in dialysis patients and, 448–462
normal physiology of, 213
Patient autonomy, increased transplantation and survival of dialysis patients, 730–742
Peak oxygen uptake, rationale for intradialytic exercise training in ESRD, 912–916
Pediatric patients. See Children
Percutaneous balloon cryoplasty, for anastomotic venous stenosis hemodialysis grafts, 2:E27
Percutaneous coronary interventions, outcomes for CKD patients, 1002–1009
Perinuclear antineutrophil cytoplasmic autoantibody (P-ANCA), in long-standing type 2 diabetes mellitus, 429–434
Periodontal disease, renal insufficiency and, 650–657
Peripheral blood stem cell transplant. See Stem cell transplant
Peripheral vascular disease, evaulation in adults and pediatric patients, S3:43–44
Peritoneal clearance, of oral-dose voriconazole in peritoneal dialysis, 162–166
Peritoneal dialysis
association of corneal calcification with vascular calcification in, 550–556
association of volume status and nutritional status, 891–902
effect on arterial wall properties, 965–977
ESRD, effect of physical activity on mortality rates, 690–701
Mycobacterium simiae as peritonitis pathogen in, 5:E75
outcome, circulating soluble vascular cell adhesion molecule 1 and, 715–729
patient autonomy association with increased transplantation and survival, 730–742
peritonitis rate comparison of CCPD and CAPD, 372–280
pharmacokinetics of oral-dose voriconazole in, 162–166
for phenytoin intoxication, 189–192
randomized controlled trials, 775–779
sildenafil for erectile dysfunction in male patients, 381–387
Peritoneal sclerosis, acute-onset, steroid-sensitive, encapsulating in kidney transplant recipient, 2:E33
Peritonitis
development, CCPD vs. CAPD, 372–380
from Mycobacterium simiae , 5:E75
Pharmacists, in chronic kidney disease management, 1105–1118
Pharmacoepidemiology, risk of ARF in nonsteroidal anti-inflammatory drug users, 531–539
Pharmacokinetics
of lorazepam and midazolam in CVVH patients, 360–371
of oral-dose voriconazole in peritoneal dialysis, 162–166
Phenytoin intoxication, in critically ill patients, 189–192
Phosphate, serum
carotid intimal-medial thickness in hemodialysis patients and, 859–865
in metabolic syndrome, 851–858
Phosphatonins, normal physiology of, 214
Phosphorus
abnormalities, management guidelines for dialysis patients, S3:69–75
normal physiology of, 213–215
Physical activity. See also Exercise
guidelines for dialysis patients, S3:60–67
mortality rates in ESRD and, 690–701 PKHD1 mutation, haplotype analysis in ARPKD, 77–87
Plasma exchange
for fibrate-induced rhabdomyolysis in ESRD, 3:E57
for posttransplantation cytomegalovirus-induced recurrence of atypical HUS, 1:E12
Pleiotropic effects, of statins in kidney, 2–14
Podocyte excretion, in diabetic nephropathy, effect of LDL aphresis on, 48–53
Point mutation, of CPT II gene, with rhabdomyolysis and ARF, 596–602
Polymorphisms, risk of renal injury after coronary bypass graft surgery and, 519–530
Polyuria, reversible nephrogenic diabetes insipidus and, 626–637
Population-based cohort, renal duplex sonography parameters associated with renal parenchymal changes in elderly, 842–850
Population study, of nutrient intake and microalbuminuria in middle age nondiabetics, 256–266
Postexposure prophylaxis, for tularemia in healthcare worker, 926–929
Postmenopausal women, hormone therapy and reduced urinary albumin excretion in, 1019–1025
Postoperative period, risk of renal injury after CABG, genetic polymorphisms and, 519–530
Posttransplantation nephrotic syndrome, caused by recurrence of glomerular disease, 1129–1135
Potassium
dietary ingestion, progression of chronic kidney disease and, 176–188
disorders, nephrology core curriculum for, 946–949
progression of cardiovascular disease and, 233–247
Prediction equations, for Chinese chronic kidney disease patients, 463–472
Preeclampsia, microscopic hematuria in pregnancy and, 667–673
Pregnancy
microscopic hematuria in, 667–673
outcome, maternal urine albumin excretion and, 1010–1018
Prenatal diagnosis, of autosomal recessive polycystic kidney disease, haplotype analysis for, 77–87
Preterm birth, albuminuria and, 1010–1018
Primary amyloidosis, melphalan conditioning, acute renal insufficiency after, 102–111
Primary cilia, proximal tubular motile, in renal sarcoidosis with hypercalcemia, 1096–1099
Progesterone, urinary albumin excretion in postmenopausal women and, 1019–1025
Prognosis, of ARF after cardiac surgery for carcinoid heart disease, 826–832
Prognostic markers, for renal dysfunction in children with MPGN-1, 510–518 Propionibacterium acnes , in pathogenesis of renal sarcoidosis, 580–587
Protective benefits, of physical activity in ESRD, 690–701
Protein A, for rapid resolution of erythropoietin-induced pure red cell aplasia, 6:E97
Protein/creatinine ratio, urinary, increased, prediction from dipstick data, 833–841
Proteinuria
and chronic renal failure in Fabry disease, 5:E82
in idiopathic glomerular capillary endotheliosis, 1090–1095
lipoprotein(a) levels in chronic kidney disease and, 28–38
pathological, prediction from dipstick data, 833–841
reduction and progression in diabetic renal failure patients with overt nephropathy, 281–287
in salt-sensitive patients, chronic kidney disease progression and, 176–188
statins and, 2–14
Proximal tubule, motile cilia in renal sarcoidosis with hypercalcemia, 1096–1099
Psychological factors, guidelines for dialysis patients, S3:60–67
Psychological interventions, to improve adherence to fluid-intake restrictions for hemodialysis patients, 15–27
Psychosocial factors, cognitive impairment in dialysis patients and, 448–462
Pulmonary hemorrhage, recurrent Goodpasture’s disease with autoreactive IgA antibodies, 397–406
Pulmonary-renal syndrome
associated with anti-GBM autoantibodies and type IV collagen defects, 743–748
in newborn with placental transmission of ANCAs, 758–761
Pulse wave velocity
arterial stiffness in chronic kidney disease, 494–501
decreasing, in hemodialysis patients, 866–874
determination of arterial stiffness in renal patients, 965–977
Pure red cell aplasia, immunoadsorption therapy with protein A columns for, 6:E97
Quality of life (QOL)
in chronic kidney disease, 658–666
daily hemodialysis and, 793–797
for menopausal women with chronic kidney disease, 66–76
rationale for intradialytic exercise training in ESRD, 912–916
Race
genetic polymorphisms associated with renal injury after CABG, 519–530
lipoprotein(a) levels in chronic kidney disease and, 28–38
Randomized controlled trials (RCTs). See also specific randomized controlled trials
Cochrane Renal Group Report on, 775–779
cognitive behavioral therapy to improve hemodialysis fluid restrictions, 1046–1057
of safety/efficacy of cholesterol-lowering drugs in CKD, 607–609
Rapidly progressive glomerulonephritis, systemic lupus erythematosus and, 950–955
}Recombinant human erythropoietin. See Erythropoietin, recombinant human
}Regional citrate anticoagulation, safety/efficacy in long-term hemodialysis, 557–564
Regular dialysis treatment, calcium oxalate supersaturation from intravenous vitamin C, 540–549
Rehabilitation, rationale for intradialytic exercise training in ESRD, 912–916
Reimbursement, for delivering medications in dialysis field, 917–925
Rejection process, infiltrating cell types in transplant glomerulitis, 1084–1089
Renal artery peak systolic flow velocity, in elderly, blood pressure and, 842–850
Renal biopsy, immunoperoxidase vs. immunofluorescence for evaluation of renal biopsy, 674–683
Renal cell carcinoma, chromophobe, in pediatric living-related kidney transplant recipient, 6:E105
Renal cortical necrosis, in type III cryoglobulinemia, 5:E79
Renal dialysis, deaths, family perspectives on, 154–161
Renal disease progression
dipstick data for predicting proteinuria of, 833–841
in elderly, renal duplex sonography parameters and, 842–850
metabolic acidosis of chronic kidney disease and, 978–993
Renal duplex sonography, parameters associated with renal parenchymal changes in elderly, 842–850
Renal fibromuscular dysplasia, in elderly, 4:E63
Renal function
acute hepatitis in kidney transplant recipient and, 193–196
IgA nephropathy with crescents in kidney transplant recipients, 167–175
pleiotropic effects of statins and, 2–14
Renal granuloma, with common variable immunodeficiency and hypocalcemia, 5:E90
Renal hyperparathyroidism, localization method for hyperplastic parathyroid glands, 344–352
Renal insufficiency
after high-dose melphalan for primary systemic amyloidosis, 102–111
in diabetic nephropathy, proteinuria reduction and, 281–287
from multiple myeloma, 619–623
Renal osteodystrophy, hemodialysis complications, nephrology core curriculum, 1125–1126
Renal parenchymal changes, in elderly, renal duplex sonography parameters and, 842–850
Renal replacement therapy. See also specific renal replacement modalities
}dosage for acute renal failure, 1136–1140
effect on arterial wall properties, 965–977
for ESRD, comparison of modalities for, 437–447
heart disease with hypertension and diabetes in ESRD, 316–323
Renal sarcoidosis, complement activation via lectin pathway in, 580–587
Renal transplantation. See also Kidney transplant recipients
outcomes, disparities in, self-care focus and, 935–940
randomized controlled trials, 775–779
rates, patient autonomy and, 730–742
Renal Treatment Satisfaction Questionnaire, for chronic kidney failure, 572–579
Renal tubular acidosis, nephrology core curriculum, 942–944
Renal tubule, hypouricemia in severe acute respiratory syndrome and, 88–95
Renin-angiotensin system, arterial stiffness in hemodialysis patients and, 866–874
Renoprotection, use of angiotensin-receptor blocking agent to reduce proteinuria, 281–287
Renovascular hypertension, severe unilateral, mast cell chymase in ischemic kidney of, 3:E45
Residual renal function, circulating soluble vascular cell adhesion molecule 1 and, 715–729
Resistance training, intradialytic, rationale for in ESRD, 912–916
Resistive index, in elderly, renal duplex sonography parameters and, 842850
Respiratory acidosis, nephrology core curriculum, 945
Respiratory alkalosis, nephrology core curriculum, 945
Restless legs syndrome, in kidney transplant recipients, 388–396
Rhabdomyolysis
with ARF, carnitine palmitoyltransferase II deficiency and, 596–602
fibrate-induced in ESRD, plasma exchange for, 3:E57
Risk stratification, guidelines for dialysis patients, S3:106–114
Salt intake, progression of chronic kidney disease and, 176–188
Sarcoidosis
with hypercalcemia, proximal tubular motile cilia in, 1096–1099
renal impairment in child, infliximab therapy for, 411–414
Scleroderma renal crisis, in kidney transplant recipient despite angiotensin II blockade, 930–934
Screening methods
for chronic kidney disease, 201–208
dipstick data for predicting proteinuria, 833–841
Secondary hyperparathyroidism, with thoracic hemorrhage originating from ectopic mediastinal parathyroid gland, 6:E109
Secondary renal involvement, in pediatric acute renal failure, 96–101
Selenium, microalbuminuria and, 248–255
Self-care, renal transplantation outcomes and, 935–940
Seroconversion patterns, HCV, in hemodialysis patients, 334–343
Sestamibi scintigraphy, with high-resolution ultrasonography for localization of hyperplastic parathyroid glands, 344–352
Severe acute respiratory syndrome (SARS), renal hypouricemia in, 88–95
Short daily hemodialysis, gabapentin-induced myopathy and, 6:E100
Short-duration, high-efficiency hemodialysis, vs. daily hemodialysis, 793–797, 798–803
Sildenafil (Viagra), for erectile dysfunction in male peritoneal dialysis patients, 381–387
Simvastatin, safety/efficacy for chronic kidney disease patients, 473–484, 607–609
SLE. See Systemic lupus erythematosus
Sleep apnea syndrome, in ESRD, coronary artery disease and antioxidant status in, 875–882
Sleep disorders, cognitive impairment in dialysis patients and, 448–462
Smoking, guidelines for dialysis patients, S3:60–67
Specific gravity, urinary, in predicting pathological proteinuria, 833–841
Standardized mortality ratio, effect of URR and hematocrit improvement on, 127–135
Standard of care, rationale for intradialytic exercise training in ESRD, 912–916
Statins
mortality reduction in hemodialysis patients and, 119–126
pleiotropic effects in kidney, 2–14
safety/efficacy for chronic kidney disease patients, 473–484, 607–609
Stem cell transplant
with high-dose melphalan for primary amyloidosis, 102–111
nephrotic syndrome in, 780–785
Stents, outcomes of percutaneous coronary interventions in CKD patients, 1002–1009
Steroid therapy, for idiopathic glomerular capillary endotheliosis, 1090–1095
Stone formers, fatty acid intake in, 267–274
Stroke, in maintenance hemodialysis patients, 1058–1066
Supersaturation, calcium oxalate, from long-term intravenous vitamin C supplementation, 540–549
Survival
after kidney transplant, strategies for preventing bone disease and, 638–649
disparities of kidney transplant recipients, self-care and, 935–940
of hemodialysis patients, dialzyer membrane permeability and, 565–571
outcomes of percutaneous coronary interventions in CKD, 1002–1009
patient autonomy and, 730–742
physical activity in ESRD and, 690–701
of vascular access in children and young adults on long-term hemodialysis, 708–714
Systematic review of literature, on psychological interventions to improve adherence to fluid-intake restrictions in hemodialysis patients, 15–27
Systemic lupus erythematosus (SLE)
case report, 219–222
long-term prognosis for renal transplantation and, 903–911
rapidly progressive glomerulonephritis and, 950–955
T cells, in transplant glomerulitis, peritubular capillary C4d deposition and, 1084–1089
Telomere length shortening, chronic inflammation in long-term hemodialysis and, 353–359
Tenofovir-induced nephrotoxicity, pathogenesis and clinical consequences, 804–817
Terbutaline, subcutaneous weight-based dosing for hyperkalemia therapy in CKD, 1040–1045
Terminal care, family perspectives on ESRD deaths, 154–161
Third National Health and Nutrition Examination Survey (NHANES), microalbuminuria and antioxidant status in U.S. adults, 248–255
Thoracic hemorrhage, from ectopic mediastinal parathyroid gland, secondary hyperparathyroidism with CRF, 6:E109
Thoracic surgery, for carcinoid heart disease, ARF after, 826–832
Thrombocytic microangiopathy, late-onset, with factor H mutation, 588–595
Thrombotic complications, in kidney transplant recipients with systemic lupus erythematosus, 903–911
Thrombotic microangiopathy
antiviral-induced, 804–817
associated with imatinib mesylate therapy for idiopathic hypereosinophilic syndrome, 762–768
Thrombotic thrombocytopenic purpura, associated with imatinib mesylate, 762768
Thyroid function, metabolic acidosis of chronic kidney disease and, 978–993
Total body water, nutritional status in peritoneal dialysis patients and, 891–902
Trandolapril, improvement of arterial stiffness in hemodialysis patients, 866–874
Transforming growth factor-β, gremlin expression in diabetic nephropathy and, 1034–1039
Transitional cell carcinoma, aristolochic acid-associated nephropathy and, 407–410
Transplant glomerulitis, infiltrating cell types in, 1084–1089
Treatment satisfaction, condition-specific measures of, 572–579
Troponin, current knowledge of, S3:81–82
Tubular dysfunction, antiviral-induced, 804–817
Tubulointerstitial fibrosis, gremlin expression in diabetic nephropathy and, 1034–1039
Tularemia, in kidney transplant recipient, 926–929
Tumor necrosis factor-β antibody, for isolated sarcoid granulomatous interstitial nephritis in child, 411–414
Type 2 diabetes, fenofibrate reduction of microalbuminuria progression in, 485–493
Type IV collagen defects, in pulmonary-renal syndrome, 743–748
United Kingdom Heart and Renal Protection Study (UK-HARP-I), safety/efficacy of simvastatin and aspirin in CKD, 473–484, 607–609
United States Renal Data System, Annual Data Report for 2004, S1:1–270
Urea clearance
improvement in dysfunctional hemodialysis catheters by reversing line position, 883–890
vascular access in pediatric hemodialysis patients and, 303–308
Uremia, atherosclerotic cardiovascular events in nondiabetic predialysis patients and, 39–47
Uric acid, in severe acute respiratory syndrome, 88–95
Urinalysis, dipstick data for predicting proteinuria, 833–841
Urinary protein/creatinine ratio, increased, prediction from dipstick data, 833–841
Urinary specific gravity, in predicting pathological proteinuria, 833–841
Urine acidification, metabolic acidosis of chronic kidney disease and, 978–993
Urine sediment, ongoing tubular injury, acute renal insufficiency after high-dose melphalan, 102–111
Urine volume, reversible nephrogenic diabetes insipidus and, 626–637
Valvular calcification, guidelines for dialysis patients, S3:69–75
Valvular heart disease, evaulation in adults and pediatric patients, S3:27–29
Vascular access
hemodialysis complications, nephrology core curriculum, 1119–1121
thrombosis, hyperhomocysteinemia and, 702–707
urea clearance, anemia management and serum albumin in pediatric patients, 303–308
urea clearance, anemia management and serum albumin in pediatric patients and, 303–308
Vascular assess
survival, in children and young adults on long-term hemodialysis, 708–714
Vascular calcification
association with corneal calcification in dialysis patients, 550–556
guidelines for dialysis patients, S3:69–75
Vascular cell adhesion molecule 1, residual renal function, cardiac hypertrophy and peritoneal dialysis outcome, 715–729
Vascular endothelial growth factor, glomerular gene expression in diabetic nephropathy and, 288–294
Vasculitis
in long-standing type 2 diabetes mellitus, 429–434
in newborn with placental transmission of ANCAs, 758–761
Vertebrobasilar territory infarction, in maintenance hemodialysis patients, 1058–1066
Viagra (sildenafil), for erectile dysfunction in male peritoneal dialysis patients, 381–387
Vitamin C, long-term intravenous supplementation, calcium oxalate supersaturation in hemodialysis patients, 540–549
Vitamin D
normal physiology of, 213–214
in preventing bone disease in kidney transplant recipients, 638–649
Vitamin E, microalbuminuria and, 248–255
Vk3 subgroup of variability, induction of Fanconi syndrome in Waldenström macroglobulinemia, 749–757
Volume status, nutritional status in peritoneal dialysis patients and, 891–902
Voriconazole, pharmacokinetics in peritoneal dialysis, 162–166
Waldenström macroglobulinemia, Vκ3 light chain induction of Fanconi syndrome in, 749–757
Wilms tumor, novel familial WT1 read-through mutation with slow progressive nephropathy, 1100–1104
Window period, of HCV infection in hemodialysis patients, 334–343
Withholding treatment, family perspectives on ESRD deaths, 154–161
x1/x2 chains of type IV collagen, recurrent Goodpasture disease and, 397–406